AdCLD-CoV19
id:
adcld-cov19-241-2677180
title:
AdCLD-CoV19
text:
AdCLD-CoV19 is a COVID-19 vaccine candidate developed by Cellid Co, a company from South Korea. A phase 1/2 trial of a single injection of AdCLD-CoV19 began in December 2020 in South Korea. In September 2021, a phase 1 trial began for a single injection of another version, named AdCLD-CoV19-1.
Preclinical studies of a single dose in mice and non-human primates for this vaccine candidate were published in April 2022. In August 2022, a phase 2 trial of 1 or 2 doses of AdCLD-CoV19-1 was registered.
brand slug:
wiki
category slug:
encyclopedia
description:
Vaccine candidate against COVID-19
original url:
https://en.wikipedia.org/wiki/AdCLD-CoV19
date created:
date modified:
2024-02-28T11:09:34Z
main entity:
{"identifier":"Q108415181","url":"https://www.wikidata.org/entity/Q108415181"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/9/94/Coronavirus._SARS-CoV-2.png","width":2048,"height":2048}
fields total:
13
integrity:
15